UCAR T-cell therapy for myasthenia gravis that hasn't responded to treatment
Treatments studied
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This trial tests an experimental therapy using special immune cells (UCAR T-cells) to target and destroy certain B cells that produce the antibodies causing myasthenia gravis. It's for people whose symptoms are not well controlled by standard treatments and may offer a new option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have myasthenia gravis that has not improved with at least one immunosuppressant for over a year, or you can't tolerate immunosuppressants.
- Your MG-ADL score is at least 5, and your eye symptoms are less than half of the total score (meaning you have more than just eye weakness).
- You need regular plasma exchange or IVIG infusions to manage symptoms.
- Your blood tests show positive CD19 or BCMA on your B cells.
- Your major organs must be functioning well (adequate blood counts, liver and kidney function).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a new type of immune cell therapy (UCAR T cells) for autoimmune diseases that have not responded to usual treatments. The therapy targets specific markers on immune cells to potentially calm the overactive immune response causing your illness.
This trial is testing a new type of cell therapy called CAR-T that targets two proteins (CD19 and BCMA) on certain immune cells. It aims to help people with severe myasthenia gravis that has not improved with standard treatments.
This trial tests a new cell therapy (CAR-T cells) for people with generalized myasthenia gravis. It aims to reduce symptoms and improve daily life by targeting and destroying faulty immune cells.
This trial tests a new immune cell treatment (CAR T-cells) for people with generalized myasthenia gravis that has not improved with standard treatments. It aims to reduce symptoms by targeting and calming the immune system's attack on muscles.
This trial tests a new type of immune cell therapy (CAR T-cells) that targets CD19 and BCMA proteins on B cells. It is for people with certain neurological autoimmune diseases that have come back or not responded to standard treatments. The goal is to see if this therapy can help control the disease.
This trial tests a new cell therapy called anitocabtagene autoleucel (anito-cel) for people with generalized myasthenia gravis (gMG) that is not well controlled with current treatments. The goal is to see if it can reduce symptoms and improve quality of life.
Hear when a new Myasthenia Gravis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.